Search | IOVS | ARVO Journals

Showing 1 – 20 of 60

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

The role of cumulative dosage on retinal structural changes in patients with HCQ retinopathy

Alice Miriam Kitay; Jay Chhablani; Catharina Busch; Swen Schwarz; DINAH ZUR; Matthew Driban; Kiran Kumar Vupparaboina; Daniel Barthelmes; Mayss Al-Sheikh

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):682 – F0136. doi:

ARVO Annual Meeting Abstract June 2022

Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical Practice: the Fight Retinal Blindness! Registry

Pierre-Henry GABRIELLE; Vuong Nguyen; Jennifer J Arnold; David Squirrell; Louis Arnould; Jorge Sanchez-Monroy; Francesco Viola; Louise O’ Toole; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1344 – F0178. doi:

ARVO Annual Meeting Abstract June 2022

Intrafamilial phenotypic variability in a large family with autosomal dominant RP1 associated Retinitis pigmentosa, and novel RP1 variants in autosomal recessive RP

Moreno Menghini; Samuel Koller; David Grubich Atac; Silke Feil; Fatma Kivrak Pfiffner; Lucy Bähr; Istvan Magyar; Angela Bahr; Daniel Barthelmes; Wolfgang Berger

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1593 – A0382. doi:

ARVO Annual Meeting Abstract June 2022

Spatial and temporal distribution of recurrent fluid in neovascular AMD quantified with a deep learning algorithm

Veronika Röggla; Gregor Sebastian Reiter; Philipp Fuchs; Oliver Leingang; Leonard Mana Coulibaly; Hrvoje Bogunovic; Daniel Barthelmes; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3019 – F0289. doi:

ARVO Annual Meeting Abstract June 2022

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Adrian Hunt; Vuong Nguyen; Sanjeeb Bhandari; Jennifer J Arnold; Ian McAllister; Hemal Mehta; Alessandro Invernizzi; David Squirrell; Theodorus Ponsioen; Pierre-Henry GABRIELLE; Louise O’ Toole; Javier Zarranz-Ventura; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2674. doi:

ARVO Annual Meeting Abstract June 2022

Analysis of AI-quantified fluid dynamics over time and their impact on visual acuity in real-world patients with neovascular age-related macular degeneration

Philipp Fuchs; Leonard Coulibaly; Hrvoje Bogunovic; Oliver Leingang; Anastasiia Gruber; Daniel Barthelmes; Gregor Sebastian Reiter; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1333 – F0167. doi:

ARVO Annual Meeting Abstract June 2022

Assessing choroidal nevi, melanomas and indeterminate melanocytic lesions using multimodal imaging – a retrospective chart review

Sandrine Zweifel; Fredy Geiger; Sadiq Said; Anahita Bajka; Mario Toro; Maximilian Wiest; Daniel Barthelmes; Marc Stahel

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1005 – F0252. doi:

ARVO Annual Meeting Abstract June 2022

Artificial intelligence to identify conventional treatment patterns in neovascular age-related macular degeneration in a real-world population

VIRGINIA DE SOUZA LEOLINO MARES; Hrvoje Bogunovic; Oliver Leingang; Daniel Barthelmes; Gregor Sebastian Reiter; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3014 – F0284. doi:

Articles November 2021

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

PDF

Pierre-Henry Gabrielle; Vuong Nguyen; Jennifer J. Arnold; Sanjeeb Bhandari; Francesco Viola; Odette A. M. Tigchelaar-Besling; Gonzaga Garay-Aramburu; Louise O'Toole; Chui Ming Gemmy Cheung; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark Gillies
TAGS: atrophoderma maculatum, exudative age-related macular degeneration, eye, fibrosis
Trans. Vis. Sci. Tech.. 2021; 10(13):5. doi: https://doi.org/10.1167/tvst.10.13.5

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

COVID-19 pandemic lockdown international impact on nAMD, DME and RVO intravitreal therapy outcomes: Fight Retinal Blindness International registry

Javier Zarranz-Ventura; Vuong Nguyen; Catherine P Creuzot Garcher; Frank D Verbraak; Louise OToole; Alessandro Invernizzi; Francesco Viola; David Squirrell; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):311. doi:

ARVO Annual Meeting Abstract June 2021

Variation in visual outcomes for neovascular age-related macular degeneration within and between practitioners

Vuong Nguyen; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):455. doi:

ARVO Annual Meeting Abstract June 2020

Association between anatomical and clinical outcomes in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Mark C Gillies; Vuong Nguyen; Calvo Pilar; Martin Puzo; Pierre-Henry GABRIELLE; Catherine P Creuzot Garcher; Florian Baudin; Benjamin Wolff; Louise O’ Toole; Laurent Castelnovo; Michel Guillaume; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4214. doi:

ARVO Annual Meeting Abstract June 2020

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

SANJEEB BHANDARI; Vuong Nguyen; Samantha Fraser-Bell; Hemal Mehta; Francesco Viola; Florian Baudin; Pierre-Henry Gabrielle; Catherine P Creuzot Garcher; Mark C Gillies; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3289. doi:

ARVO Annual Meeting Abstract July 2019

Observation of ranibizumab treatment in real-life conditions – an interim analysis of the myopic choroidal neovascularization (mCNV) population within the observational, non-interventional PACIFIC study

Kristina Markova; Christos Haritoglou; Matthias Iwersen; Ulrike Michel; Martina Junge; Peter Geuking; Katrin Lorenz; Thomas Ach; Ramin Khoramnia; Andreas Schmidt; Judith Becker; Erik Beeke; Mathias Müller-Holz; Daniel Barthelmes; Focke Ziemssen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4320. doi:

ARVO Annual Meeting Abstract July 2019

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

SANJEEB BHANDARI; Anne Catherine Biechl; Jennifer Joan Arnold; Stephanie Young; Samanta Fraser-Bell; Hemal Mehta; Mark C Gillies; Daniel Barthelmes; Vuong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2602. doi:

ARVO Annual Meeting Abstract July 2019

Real-world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting

Sarah Ah-Moye; Pardis Zalmay; Magnus Theodorsson; Martin Lynn Harris; Riaz Asaria; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Vuong Nguyen; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4061. doi:

ARVO Annual Meeting Abstract July 2019

Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration

Mark C Gillies; SANJEEB BHANDARI; Benjamin Wolff; Jennifer Joan Arnold; Rohan W Essex; Stephanie Young; David M Squirrell; Daniel Barthelmes; Vuong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):111. doi:

ARVO Annual Meeting Abstract July 2019

Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months

Vuong Nguyen; Anagha Vaze; Samanta Fraser-Bell; Jennifer Joan Arnold; Rohan W Essex; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):139. doi:

ARVO Annual Meeting Abstract July 2018

Trainee-led vs. specialist-led management of neovascular age-related macular degeneration.

Rohan W. Essex; Vuong Nguyen; Vincent Daien; Sarah Steinmann; Richard Walton; Mark C Gillies; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1463. doi:

ARVO Annual Meeting Abstract July 2018

Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.

Charles Hennings; Mira Deshmukh; Vuong Nguyen; Martin Harris; Riaz Asaria; Daniel Barthelmes; Mark C Gillies; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3616. doi:

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

The role of cumulative dosage on retinal structural changes in patients with HCQ retinopathy

Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical Practice: the Fight Retinal Blindness! Registry

Intrafamilial phenotypic variability in a large family with autosomal dominant RP1 associated Retinitis pigmentosa, and novel RP1 variants in autosomal recessive RP

Spatial and temporal distribution of recurrent fluid in neovascular AMD quantified with a deep learning algorithm

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Analysis of AI-quantified fluid dynamics over time and their impact on visual acuity in real-world patients with neovascular age-related macular degeneration

Assessing choroidal nevi, melanomas and indeterminate melanocytic lesions using multimodal imaging – a retrospective chart review

Artificial intelligence to identify conventional treatment patterns in neovascular age-related macular degeneration in a real-world population

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

COVID-19 pandemic lockdown international impact on nAMD, DME and RVO intravitreal therapy outcomes: Fight Retinal Blindness International registry

Variation in visual outcomes for neovascular age-related macular degeneration within and between practitioners

Association between anatomical and clinical outcomes in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

Observation of ranibizumab treatment in real-life conditions – an interim analysis of the myopic choroidal neovascularization (mCNV) population within the observational, non-interventional PACIFIC study

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

Real-world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting

Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration

Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months

Trainee-led vs. specialist-led management of neovascular age-related macular degeneration.

Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.

To View More...

You must be signed into an individual account to use this feature.